# ANGIOTAX

Source: https://onco.cc/trials/angiotax/  
OnCo record `angiotax` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A small French trial showed weekly paclitaxel controls angiosarcoma in most patients for a few months, making it the standard drug for this rare vascular cancer.

## Summary

ANGIOTAX was a single-arm phase 2 trial of the French Sarcoma Group in which 30 patients with unresectable or metastatic angiosarcoma received weekly paclitaxel 80 mg/m2. Most patients were free of progression at two months, the primary endpoint, with responses concentrated in cutaneous scalp and face angiosarcoma, and toxicity was mild. Published in the Journal of Clinical Oncology in 2008, it made weekly paclitaxel the reference systemic treatment for angiosarcoma; the successor ANGIOTAX-PLUS trial found that adding bevacizumab did not improve outcomes.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-17
- Tags: subtype-page
- Phase: 2
- Setting: Unresectable or metastatic angiosarcoma: weekly paclitaxel
- Sponsor: French Sarcoma Group
- Enrolled: 30
- Result: Primary endpoint met: most patients progression-free at two months; responses mainly in cutaneous scalp and face disease.

## Sources

- Journal of Clinical Oncology 2008: https://doi.org/10.1200/JCO.2008.17.3146

## Connected records

- cancers: [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)](https://onco.cc/cancers/vascular-tumours/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/angiotax.json